Skip to main content
PHVS
NASDAQ Life Sciences

Pharvaris Closes $132.3M Public Offering, Including Full Over-Allotment Exercise

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$30
Mkt Cap
$1.959B
52W Low
$14.585
52W High
$31.65
52W Position info
106% above low
Off High info
5.2% below high
Rel. Volume info
3.7× avg
Market data snapshot near publication time

PHVS has more than doubled off its 52-week low of $14.585 on elevated volume (3.7× avg).

Summary

Pharvaris N.V. has successfully closed its underwritten public offering, raising approximately $132.3 million in gross proceeds, which includes the full exercise of the over-allotment option.


Key Events · Financing and Capital Events · PHVS

  • Offering Closed

    Pharvaris N.V. completed its underwritten public offering on May 11, 2026, following the underwriting agreement dated May 8, 2026.

  • Substantial Capital Raised

    The company raised approximately $132.3 million in gross proceeds by selling 4,455,863 ordinary shares at a public offering price of $29.68 per share. Net proceeds are expected to be approximately $124 million.

  • Full Over-Allotment Exercise

    The underwriters fully exercised their option to purchase an additional 581,199 ordinary shares, indicating strong demand for the offering.

  • Funding for Clinical Programs and Commercialization

    Proceeds will primarily fund research and development expenses for late-stage clinical programs, expand the U.S. sales and marketing team, and cover general corporate purposes.


Analysis · PHVS · Life Sciences

This filing confirms the successful closing of a substantial public offering, including the full exercise of the underwriters' over-allotment option, which increased the total capital raised to approximately $132.3 million. This significant funding provides crucial runway for Pharvaris's late-stage clinical programs and commercialization efforts, especially following recent positive clinical data. The strong demand, evidenced by the full over-allotment exercise, indicates investor confidence in the company's prospects despite the dilutive nature of the offering.

At the time of this filing, PHVS was trading at $30.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $14.59 to $31.65. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PHVS - Latest Insights

PHVS
Jul 06, 2026, 6:50 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $34.42
Real-time Price: $34.91 info
Change: +$0.490 (+1%) info
Market Cap: $2.439B info
PHVS
Jun 11, 2026, 6:52 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $32.13
Real-time Price: $34.91 info
Change: +$2.78 (+9%) info
Market Cap: $2.439B info
PHVS
May 12, 2026, 4:21 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $31.25
Real-time Price: $34.91 info
Change: +$3.66 (+12%) info
Market Cap: $2.439B info
PHVS
May 12, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $32.00
Real-time Price: $34.91 info
Change: +$2.91 (+9%) info
Market Cap: $2.439B info
PHVS
May 11, 2026, 4:15 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $30.00
Real-time Price: $34.91 info
Change: +$4.91 (+16%) info
Market Cap: $2.439B info